当前位置: X-MOL 学术Sci. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors.
Scientific Reports ( IF 4.6 ) Pub Date : 2020-07-07 , DOI: 10.1038/s41598-020-68087-y
Takahito Moriyama 1 , Kazunori Karasawa 1 , Yoei Miyabe 1 , Kenichi Akiyama 1 , Shota Ogura 1 , Tomo Takabe 1 , Naoko Sugiura 1 , Momoko Seki 1 , Yuko Iwabuchi 1 , Keiko Uchida 1 , Kosaku Nitta 1
Affiliation  

The Oxford classification for IgA nephropathy (IgAN) was updated in 2017. We have validated the revised Oxford classification considering treatment with corticosteroids/immunosuppressors. In this retrospective analysis, 871 IgAN patients were enrolled. Patients were divided into two groups, those treated with or without corticosteroids/immunosuppressors. The 20-year renal prognosis up to end-stage renal disease was assessed using the Oxford classification. In all patients, the renal survival rate was 87.5% at 10 years and 72.6% at 20 years. The T score alone was significantly related to renal prognosis in the Kaplan–Meier analysis and multivariate Cox regression analysis. In the non-treatment group (n = 445), E, S, T, and C scores were significantly related to renal survival rates, however, in the treatment group (n = 426), T score alone was significantly related to renal prognosis on Kaplan–Meier analysis, indicating that corticosteroids/immunosuppressors improved renal prognosis in E1, S1, and C1. In patients with E1, S1, or C1, the treatment group showed significantly better renal prognosis than the non-treatment group in univariate and multivariate analysis. The Oxford classification and T score were used to determine renal prognosis in IgAN patients. Corticosteroids/immunosuppressors improved renal prognosis, especially E1, S1, and C1 scores.



中文翻译:

考虑使用糖皮质激素/免疫抑制剂治疗的IgA肾病修订牛津分类的验证。

IgA肾病(IgAN)的牛津分类于2017年更新。考虑到使用皮质类固醇/免疫抑制剂治疗,我们已经验证了修订后的牛津分类。在这项回顾性分析中,招募了871名IgAN患者。患者分为两组,接受或不接受皮质类固醇/免疫抑制剂治疗的患者。使用牛津分类法评估直至终末期肾脏疾病的20年肾脏预后。在所有患者中,肾脏存活率在10年时为87.5%,在20年时为72.6%。在Kaplan–Meier分析和多元Cox回归分析中,仅T评分与肾脏预后显着相关。在非治疗组(n = 445)中,E,S,T和C评分与肾脏存活率显着相关,但是在治疗组(n = 426)中,在Kaplan–Meier分析中,单独的T评分与肾脏预后显着相关,表明皮质类固醇/免疫抑制剂可改善E1,S1和C1的肾脏预后。在E1,S1或C1患者中,单变量和多变量分析显示治疗组的肾脏预后明显优于未治疗组。牛津分类和T评分用于确定IgAN患者的肾脏预后。皮质类固醇/免疫抑制剂可改善肾脏预后,尤其是E1,S1和C1评分。牛津分类和T评分用于确定IgAN患者的肾脏预后。皮质类固醇/免疫抑制剂可改善肾脏预后,尤其是E1,S1和C1评分。牛津分类和T评分用于确定IgAN患者的肾脏预后。皮质类固醇/免疫抑制剂可改善肾脏预后,尤其是E1,S1和C1评分。

更新日期:2020-07-07
down
wechat
bug